166 related articles for article (PubMed ID: 30295077)
1. Does anti-Müllerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study.
Vermeulen RFM; van Beurden M; Gaarenstroom KN; Teunis T; Kieffer JM; Aaronson NK; Kenter GG; Korse CM
Climacteric; 2018 Dec; 21(6):574-580. PubMed ID: 30295077
[TBL] [Abstract][Full Text] [Related]
2. Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
Stuursma A; van Driel CMG; Wessels NJ; de Bock GH; Mourits MJE
Maturitas; 2018 May; 111():69-76. PubMed ID: 29673834
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy.
Teixeira N; Mourits MJ; Oosterwijk JC; Fakkert IE; Absalom AR; Bakker SJL; van der Meer P; de Bock GH
Fam Cancer; 2019 Jan; 18(1):19-27. PubMed ID: 29881922
[TBL] [Abstract][Full Text] [Related]
4. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
[TBL] [Abstract][Full Text] [Related]
5. What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
Hickey M; Moss KM; Krejany EO; Wrede CD; Brand A; Kirk J; Symecko HL; Domchek SM; Tejada-Berges T; Trainer A; Mishra GD
Gynecol Oncol; 2021 Oct; 163(1):148-154. PubMed ID: 34312002
[TBL] [Abstract][Full Text] [Related]
6. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
[TBL] [Abstract][Full Text] [Related]
7. Quality of life after risk-reducing salpingo-oophorectomy in women with a pathogenic BRCA variant.
Zilski N; Speiser D; Bartley J; Roehle R; Blohmer JU; Keilholz U; Goerling U
J Sex Med; 2023 Dec; 21(1):33-39. PubMed ID: 37973412
[TBL] [Abstract][Full Text] [Related]
8. What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy.
Hickey M; Moss KM; Krejany EO; Wrede CD; Domchek SM; Kirk J; Brand A; Trainer A; Mishra GD; Baker FC
Gynecol Oncol; 2021 Aug; 162(2):447-453. PubMed ID: 34116835
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study.
Terra L; Lee Meeuw Kjoe PR; Agelink van Rentergem JA; Beekman MJ; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Mourits MJE; van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; van der Wall E; van Leeuwen FE; Schagen SB
BJOG; 2023 Jul; 130(8):968-977. PubMed ID: 36715559
[TBL] [Abstract][Full Text] [Related]
10. Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations.
Powell CB; Alabaster A; Le A; Stoller N; Armstrong MA; Raine-Bennett T
Psychooncology; 2020 Feb; 29(2):331-338. PubMed ID: 31654466
[TBL] [Abstract][Full Text] [Related]
11. What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
Moss KM; Mishra GD; Krejany EO; Hickey M
Gynecol Oncol; 2022 Oct; 167(1):58-64. PubMed ID: 35933227
[TBL] [Abstract][Full Text] [Related]
12. Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial.
van Driel C; de Bock GH; Schroevers MJ; Mourits MJ
BJOG; 2019 Feb; 126(3):402-411. PubMed ID: 30222235
[TBL] [Abstract][Full Text] [Related]
13. Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.
Vermeulen RFM; Korse CM; Kenter GG; Brood-van Zanten MMA; Beurden MV
Climacteric; 2019 Aug; 22(4):352-360. PubMed ID: 30905183
[No Abstract] [Full Text] [Related]
14. The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy.
Tucker PE; Bulsara MK; Salfinger SG; Tan JJ; Green H; Cohen PA
Maturitas; 2016 Mar; 85():42-8. PubMed ID: 26857878
[TBL] [Abstract][Full Text] [Related]
15. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.
Mai PL; Huang HQ; Wenzel LB; Han PK; Moser RP; Rodriguez GC; Boggess J; Rutherford TJ; Cohn DE; Kauff ND; Phillips KA; Wilkinson K; Wenham RM; Hamilton C; Powell MA; Walker JL; Greene MH; Hensley ML
Gynecol Oncol; 2020 Jan; 156(1):131-139. PubMed ID: 31759774
[TBL] [Abstract][Full Text] [Related]
16. Effect of risk-reducing salpingo-oophorectomy on the quality of life in Korean BRCA mutation carriers.
Chae S; Kim EK; Jang YR; Lee AS; Kim SK; Suh DH; Kim K; No JH; Kim YB; Kim SW; Kang E
Asian J Surg; 2021 Aug; 44(8):1056-1062. PubMed ID: 33573923
[TBL] [Abstract][Full Text] [Related]
17. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study.
Vermeulen RFM; Beurden MV; Kieffer JM; Bleiker EMA; Valdimarsdottir HB; Massuger LFAG; Mourits MJE; Gaarenstroom KN; van Dorst EBL; van der Putten HWHM; Aaronson NK
Eur J Cancer; 2017 Oct; 84():159-167. PubMed ID: 28818705
[TBL] [Abstract][Full Text] [Related]
18. Changes in Bone Density in Carriers of BRCA1 and BRCA2 Pathogenic Variants After Salpingo-Oophorectomy.
Chan LN; Chen LM; Goldman M; Mak JS; Bauer DC; Boscardin J; Schembri M; Bae-Jump V; Friedman S; Jacoby VL
Obstet Gynecol; 2023 Jul; 142(1):160-169. PubMed ID: 37290104
[TBL] [Abstract][Full Text] [Related]
19. Short-term impact of surgically induced menopause on cognitive function and wellbeing in women at high risk for ovarian cancer following risk-reducing bilateral salpingo-oophorectomy.
Chang H; Kamara D; Bresee C; Lester J; Cass I
Menopause; 2020 Dec; 28(4):354-359. PubMed ID: 33350669
[TBL] [Abstract][Full Text] [Related]
20. Does anti-Müllerian hormone predict menopause in the general population? Results of a prospective ongoing cohort study.
Depmann M; Eijkemans MJ; Broer SL; Scheffer GJ; van Rooij IA; Laven JS; Broekmans FJ
Hum Reprod; 2016 Jul; 31(7):1579-87. PubMed ID: 27179263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]